Italia markets open in 5 hours

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
84,63+0,20 (+0,24%)
Alla chiusura: 04:00PM EDT
84,75 +0,12 (+0,14%)
Dopo ore: 04:40PM EDT

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415 506 6700

Impiegati a tempo pieno3.401

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Alexander HardyPresident, CEO & Director1,72MN/D1969
Mr. Brian R. MuellerCFO & Executive VP1,07M2,47M1974
Dr. C. Greg Guyer Ph.D.Executive VP & CTO1,11MN/D1962
Dr. Henry J. Fuchs M.D., Ph.D.President of Worldwide Research & Development1,41MN/D1958
Ms. Erin BurkhartGroup VP & Chief Accounting OfficerN/DN/D1979
Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentN/DN/DN/D
Traci McCartyGroup Vice President of Investor RelationsN/DN/DN/D
Mr. George Eric DavisExecutive VP, Chief Legal Officer, General Counsel & Secretary1,23M2,11M1971
Ms. Humaira SerajuddinSenior VP & Chief Marketing OfficerN/DN/DN/D
Ms. Amy WiremanExecutive VP & Chief People OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Governance aziendale

L'ISS Governance QualityScore di BioMarin Pharmaceutical Inc. al 1 luglio 2024 è 3. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 2; diritti degli azionisti: 5; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.